risperidone has been researched along with Sexual Dysfunction, Physiological in 36 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Sexual Dysfunction, Physiological: Physiological disturbances in normal sexual performance in either the male or the female.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicentre, observational, prospective, nonrandomized study compared the effectiveness and tolerability of quetiapine and risperidone in the acute and long-term treatment of schizophrenia in a clinical setting." | 9.13 | A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. ( Cañas, F; Perez, V; Tafalla, M, 2008) |
| "This open-label, prospective, 4-month study in hyperprolactinemic patients with schizophrenia explored whether prolactin levels decrease after switching antipsychotic therapy to olanzapine." | 9.12 | Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. ( Ahl, J; Kinon, BJ; Liu-Seifert, H; Maguire, GA, 2006) |
| "Treatment-resistant patients (133 men, 24 women) diagnosed with DSM-IV schizophrenia or schizoaffective disorder participated in a double-blind, randomized, 14-week trial comparing clozapine (N = 40), olanzapine (N = 39), risperidone (N = 41), and haloperidol (N = 37)." | 9.11 | Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. ( Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2004) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 7.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 7.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder." | 7.73 | Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. ( Bettcher, BM; Byerly, MJ; Carmody, T; Fisher, R; Nakonezny, PA; Rush, AJ, 2006) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "This multicentre, observational, prospective, nonrandomized study compared the effectiveness and tolerability of quetiapine and risperidone in the acute and long-term treatment of schizophrenia in a clinical setting." | 5.13 | A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. ( Cañas, F; Perez, V; Tafalla, M, 2008) |
| "This open-label, prospective, 4-month study in hyperprolactinemic patients with schizophrenia explored whether prolactin levels decrease after switching antipsychotic therapy to olanzapine." | 5.12 | Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. ( Ahl, J; Kinon, BJ; Liu-Seifert, H; Maguire, GA, 2006) |
| "Outpatients with schizophrenia, who initiated or changed antipsychotic treatment, and entered this 3-year, prospective, observational study were classified according to the monotherapy prescribed at baseline: olanzapine (N=2638), risperidone (N=860), quetiapine (N=142) or haloperidol (N=188)." | 5.12 | Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. ( Akram, A; Anders, M; Araszkiewicz, A; Dossenbach, M; Dyachkova, Y; Khalil, A; McBride, M; Pecenak, J; Pirildar, S; Shakhnovich, T; Treuer, T, 2006) |
| "Treatment-resistant patients (133 men, 24 women) diagnosed with DSM-IV schizophrenia or schizoaffective disorder participated in a double-blind, randomized, 14-week trial comparing clozapine (N = 40), olanzapine (N = 39), risperidone (N = 41), and haloperidol (N = 37)." | 5.11 | Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. ( Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2004) |
| "To investigate the clinical effects of aripiprazole on sexual dysfunction induced by amisulpride or risperidone in male patients with schizophrenia." | 3.85 | [Aripiprazole for drug-induced sexual dysfunction in schizophrenic males]. ( Gao, LJ; Guo, HG; Liang, ZT; Yang, Y; Zhong, XX; Zhu, JC, 2017) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 3.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 3.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "The primary objective of the present study was to examine the relationship between sexual dysfunction, subjective well-being and prolactin levels in patients with schizophrenia treated either with risperidone or quetiapine." | 3.74 | Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. ( Albrecht, C; Bliesener, N; Cooper-Mahkorn, D; Creutz, C; Cvetanovska, G; Hornung, WP; Klingmüller, D; Kühn, KU; Lemke, MR; Maier, W; Schubert, M; Sträter, B; Westheide, J, 2008) |
| "Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder." | 3.73 | Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. ( Bettcher, BM; Byerly, MJ; Carmody, T; Fisher, R; Nakonezny, PA; Rush, AJ, 2006) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| " We report a boy with autism-spectrum disorder, who developed frequent penile erections after an increase in risperidone dosage for a month." | 1.48 | Frequent Penile Erection in a Boy With Autism-spectrum Disorder: Case Report. ( Bejrananda, T; Thongseiratch, T, 2018) |
| "Hyperprolactinaemia is a significant side effect of antipsychotic medications and may cause sexual dysfunction." | 1.39 | Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. ( Franch, J; Labad, J; López, X; Monseny, R; Montalvo, I; Ortega, L; Solé, M; Vilella, E, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (61.11) | 29.6817 |
| 2010's | 12 (33.33) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Jannini, TB | 1 |
| Sansone, A | 1 |
| Rossi, R | 1 |
| Di Lorenzo, G | 1 |
| Toscano, M | 1 |
| Siracusano, A | 1 |
| Jannini, EA | 1 |
| Krishnegowda, S | 1 |
| Udaykumar, P | 1 |
| Yadiyal, A | 1 |
| Bejrananda, T | 1 |
| Thongseiratch, T | 1 |
| Gao, LJ | 1 |
| Guo, HG | 1 |
| Liang, ZT | 1 |
| Zhong, XX | 1 |
| Zhu, JC | 1 |
| Yang, Y | 1 |
| Downing, L | 1 |
| Kim, DD | 1 |
| Procyshyn, RM` | 1 |
| Tibbo, P | 1 |
| Kalkavoura, CS | 1 |
| Michopoulos, I | 1 |
| Arvanitakis, P | 1 |
| Theodoropoulou, P | 1 |
| Dimopoulou, K | 1 |
| Tzebelikos, E | 1 |
| Lykouras, L | 1 |
| An, FR | 1 |
| Yang, R | 1 |
| Wang, ZM | 1 |
| Ungvari, GS | 1 |
| Ng, CH | 1 |
| Chiu, HF | 1 |
| Wu, PP | 1 |
| Jin, X | 1 |
| Li, L | 1 |
| Lok, GK | 1 |
| Xiang, YT | 1 |
| Konarzewska, B | 1 |
| Wołczyński, S | 1 |
| Szulc, A | 1 |
| Galińska, B | 1 |
| Popławska, R | 1 |
| Waszkiewicz, N | 1 |
| Meyer, JM | 2 |
| Moncrieff, J | 1 |
| Cohen, D | 1 |
| Mason, JP | 1 |
| van Bruggen, M | 1 |
| van Amelsvoort, T | 1 |
| Wouters, L | 1 |
| Dingemans, P | 1 |
| de Haan, L | 1 |
| Linszen, D | 1 |
| Montejo, AL | 1 |
| Majadas, S | 1 |
| Rico-Villademoros, F | 1 |
| Llorca, G | 1 |
| De La Gándara, J | 1 |
| Franco, M | 1 |
| Martín-Carrasco, M | 1 |
| Aguera, L | 1 |
| Prieto, N | 1 |
| Zhang, XR | 1 |
| Zhang, ZJ | 1 |
| Jenkins, TA | 1 |
| Cheng, WR | 1 |
| Reynolds, GP | 1 |
| Chen, CY | 1 |
| Lin, TY | 1 |
| Wang, CC | 1 |
| Shuai, HA | 1 |
| Jeong, HG | 1 |
| Lee, MS | 1 |
| Lee, HY | 1 |
| Ko, YH | 1 |
| Han, C | 1 |
| Joe, SH | 1 |
| Kandasamy, A | 1 |
| Montalvo, I | 1 |
| Ortega, L | 1 |
| López, X | 1 |
| Solé, M | 1 |
| Monseny, R | 1 |
| Franch, J | 1 |
| Vilella, E | 1 |
| Labad, J | 1 |
| Roke, Y | 1 |
| Buitelaar, JK | 1 |
| Boot, AM | 1 |
| Tenback, D | 1 |
| van Harten, PN | 1 |
| Holtmann, M | 1 |
| Gerstner, S | 1 |
| Schmidt, MH | 1 |
| Volavka, J | 1 |
| Czobor, P | 1 |
| Cooper, TB | 1 |
| Sheitman, B | 1 |
| Lindenmayer, JP | 1 |
| Citrome, L | 1 |
| McEvoy, JP | 1 |
| Lieberman, JA | 1 |
| Loh, C | 1 |
| Leckband, SG | 1 |
| Turner, E | 1 |
| Dossenbach, M | 2 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Bitter, I | 1 |
| Ahl, J | 2 |
| Kinon, BJ | 2 |
| Liu-Seifert, H | 2 |
| Kelly, DL | 1 |
| Conley, RR | 1 |
| Byerly, MJ | 2 |
| Nakonezny, PA | 2 |
| Fisher, R | 2 |
| Magouirk, B | 1 |
| Rush, AJ | 2 |
| Maguire, GA | 1 |
| Wylie, K | 1 |
| Levin, R | 1 |
| Hallam-Jones, R | 1 |
| Goddard, A | 1 |
| Dyachkova, Y | 1 |
| Pirildar, S | 1 |
| Anders, M | 1 |
| Khalil, A | 1 |
| Araszkiewicz, A | 1 |
| Shakhnovich, T | 1 |
| Akram, A | 1 |
| Pecenak, J | 1 |
| McBride, M | 1 |
| Treuer, T | 1 |
| Bettcher, BM | 1 |
| Carmody, T | 1 |
| Perez, V | 1 |
| Cañas, F | 1 |
| Tafalla, M | 1 |
| Westheide, J | 1 |
| Cvetanovska, G | 1 |
| Albrecht, C | 1 |
| Bliesener, N | 1 |
| Cooper-Mahkorn, D | 1 |
| Creutz, C | 1 |
| Hornung, WP | 1 |
| Klingmüller, D | 1 |
| Lemke, MR | 1 |
| Maier, W | 1 |
| Schubert, M | 1 |
| Sträter, B | 1 |
| Kühn, KU | 1 |
| Kelly, BD | 1 |
| Kennedy, N | 1 |
| Shanley, D | 1 |
| Kaneda, Y | 1 |
| Mullen, B | 1 |
| Brar, JS | 1 |
| Vagnucci, AH | 1 |
| Ganguli, R | 1 |
| Compton, MT | 1 |
| Storch, DD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia[NCT00505765] | Phase 2 | 63 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Survey of Sexual Function in Schizophrenic Patients[NCT01835522] | 0 participants (Actual) | Observational | 2009-07-31 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 3.9 |
| AL-108, 5 mg/Day | 4.6 |
| Placebo | 3.2 |
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 1.3 |
| AL-108, 5 mg/Day | 2.3 |
| Placebo | -0.2 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | -0.4 |
| AL-108, 5 mg/Day | -1.2 |
| Placebo | -0.3 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 0.1 |
| AL-108, 5 mg/Day | -0.6 |
| Placebo | -0.1 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 4.9 |
| AL-108, 5 mg/Day | 8.9 |
| Placebo | 0.3 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 2.9 |
| AL-108, 5 mg/Day | 7.2 |
| Placebo | -0.9 |
2 reviews available for risperidone and Sexual Dysfunction, Physiological
| Article | Year |
|---|---|
Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Male; Psychotic Disorders; Risperidone; Sex | 2022 |
Delusion and desire: erotomania revisited.
Topics: Antipsychotic Agents; Female; Hospitalization; Humans; Middle Aged; Risperidone; Schizophrenia, Para | 2000 |
6 trials available for risperidone and Sexual Dysfunction, Physiological
| Article | Year |
|---|---|
Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychi | 2011 |
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2004 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Estradiol; Female; Galactorrhea; Gynecomastia; H | 2006 |
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Halo | 2006 |
A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Drug Administration S | 2008 |
28 other studies available for risperidone and Sexual Dysfunction, Physiological
| Article | Year |
|---|---|
Association Between Sexual Dysfunction and Dose of Atypical Antipsychotics: Essential to Learn the Basics.
Topics: Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Dibenzothiazepines; Female; Humans; | 2023 |
Frequent Penile Erection in a Boy With Autism-spectrum Disorder: Case Report.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Child; Drug Substitution; Humans; Male; Penile Erect | 2018 |
[Aripiprazole for drug-induced sexual dysfunction in schizophrenic males].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Prolact | 2017 |
Management of sexual adverse effects induced by atypical antipsychotic medication
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug-Related Side Effects and Adverse | 2019 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental D | 2013 |
Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Case-Control Studies; China; Cloza | 2016 |
Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Estradiol; Gonadotropins, Pituitary; Hormones; Humans; | 2009 |
Sexual dysfunction in patients treated with atypical antipsychotics.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Erectile Dysfunction; Female; Humans; Libido | 2008 |
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.
Topics: Adult; Affect; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety Disorders; Attitude to Health; | 2009 |
Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone.
Topics: Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cross-Sectional Studies; Estradiol; Fem | 2009 |
Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Confidence Intervals; Cross-Sectional Studies; Delayed | 2010 |
The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dibenzothiazepines; Disease Models, Animal; Dop | 2011 |
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Estradiol; Follicle Stimula | 2012 |
Paliperidone as an alternative for risperidone in a case of schizophrenia with retrograde ejaculation.
Topics: Adult; Antipsychotic Agents; Ejaculation; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidi | 2012 |
Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Topics: Adult; Age Factors; Antipsychotic Agents; Biomarkers; Drug Substitution; Female; Humans; Hyperprolac | 2013 |
Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; | 2012 |
Risperidone-associated ejaculatory and urinary dysfunction in male adolescents.
Topics: Adolescent; Antipsychotic Agents; Ejaculation; Humans; Hyperprolactinemia; Male; Risperidone; Schizo | 2003 |
Risperidone-induced retrograde ejaculation: case report and review of the literature.
Topics: Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Ejaculation; Humans; Male; | 2004 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Ejaculation; Female; Humans; Hyperprolactinemia; Male; | 2004 |
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Dibenzothiazepines; Female; H | 2006 |
Sleep exacerbation of persistent sexual arousal syndrome in a postmenopausal woman.
Topics: Arousal; Female; Humans; Middle Aged; Postmenopause; Regional Blood Flow; Risperidone; Sexual Dysfun | 2006 |
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dose-Response Re | 2006 |
Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
Topics: Adult; Antipsychotic Agents; Arousal; Dibenzothiazepines; Erectile Dysfunction; Female; Humans; Libi | 2008 |
Risperidone-induced ejaculatory dysfunction: a case report.
Topics: Adult; Antipsychotic Agents; Ejaculation; Humans; Male; Psychotic Disorders; Risperidone; Sexual Dys | 2001 |
Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone.
Topics: Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Sexu | 2001 |
Risperidone-induced ejaculatory disturbances.
Topics: Adult; Antipsychotic Agents; Ejaculation; Humans; Male; Risperidone; Schizophrenia; Sexual Dysfuncti | 2002 |
Risperidone-induced retrograde ejaculation.
Topics: Adult; Ejaculation; Humans; Male; Risperidone; Schizophrenia; Serotonin Antagonists; Sexual Dysfunct | 2002 |